This is a routine board appointment with no financial data or operational changes — no immediate trading action warranted. Monitor for future 10-Q filings to assess whether Capone's diagnostics commercialization experience translates into accelerated PreTRM test adoption or reimbursement progress.
Price Chart
Executive Summary
Sera Prognostics appointed Mark Capone, former CEO of Myriad Genetics, to its Board of Directors effective July 1, 2026, and adopted a new Non-Employee Director Compensation Policy. This is a routine board appointment with no material financial impact — Mr. Capone brings diagnostics commercialization experience but the filing contains no financial data, guidance, or operational changes.
Key Facts
- Mark Capone appointed as Class II director effective July 1, 2026, with term expiring at 2029 annual meeting
- Mr. Capone also appointed to the Compensation Committee
- Mr. Capone is former CEO of Myriad Genetics (5 years) and has 40+ years in diagnostics/life sciences
- Initial equity award of lesser of $167,072 grant date fair value or 150,000 option equivalents, vesting over 3 years
- Annual subsequent equity award of lesser of $88,359 grant date fair value or 75,000 option equivalents
- Non-Employee Director Compensation Policy adopted effective July 1, 2026, with annual cash retainer of $44,063 per director
- No departures, no financial data, no guidance, no operational changes reported
Financial Impact
No material financial impact — routine board appointment with standard director compensation (initial equity award up to $167,072 grant date fair value, annual cash retainer $44,063)
Risk Factors
- No financial data or guidance provided — cannot assess operational trajectory
- Director compensation policy adds standard equity and cash costs but immaterial for a $79M market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001534969-26-000035 |
| Document: sera-ex10_1.htm | 0001534969-26-000035 |
| Document: sera-ex99_1.htm | 0001534969-26-000035 |
| Document: 0001534969-26-000035-index-headers.html | 0001534969-26-000035 |
| Document: 0001534969-26-000035-index.html | 0001534969-26-000035 |
| Document: 0001534969-26-000035.txt | 0001534969-26-000035 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $2.04 | awaiting T+60 | — | $2.04 (−0.00%) |
Oct 13, 2026 13d ago | 144 | $2.07 | awaiting T+60 | — | $2.04 (−1.45%) |
Aug 19, 2026 9w ago | 8-K | $2.10 | awaiting T+60 | — | $2.04 (−2.86%) |
Jun 30, 2026 16w ago | 8-K | $2.03 $2.11 | ▲ +3.94% | ▲ +0.98% | $2.04 (+0.49%) |
Jun 15, 2026 19w ago | Insider Cluster | $1.86 $2.05 | ▼ −10.22% | ▼ −9.22% | $2.04 (−9.68%) |
Jun 8, 2026 20w ago | 144 | $2.13 $2.01 | ▼ −5.63% | ▼ −9.45% | $2.04 (−4.23%) |
Jun 1, 2026 21w ago | 8-K | $2.04 $2.09 | ▲ +2.45% | ▲ +1.33% | $2.04 (−0.00%) |
Apr 24, 2026 26w ago | DEFA14A | $2.00 $2.08 | ▲ +4.00% | ▼ −0.78% | $2.04 (+2.00%) |
Mar 6, 2026 33w ago | Insider Cluster | $1.95 $2.19 | ▲ +12.31% | ▼ −0.47% | $2.04 (+4.62%) |
Mar 6, 2026 33w ago | Insider Cluster | $1.95 $2.19 | ▲ +12.31% | ▼ −0.47% | $2.04 (+4.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers